PSICOTERAPIA ASISTIDA CON PSILOCIBINA PARA EL TRATAMIENTO DE LA DEPRESIÓN Y LA ANSIEDAD EN PACIENTES CON CÁNCER POTENCIALMENTE MORTALES: UNA REVISIÓN DE LA LITERATURA
DOI:
https://doi.org/10.47820/recima21.v4i11.4311Palabras clave:
Psilocibina. Cáncer terminal. Psicodélico. Alucinógenos. Ansiedad. Depresión.Resumen
Introducción: La psilocibina es el principio activo de las setas de la especie Psilocybe cubensis, históricamente conocidas como setas mágicas. Es un agonista del receptor serotoninérgico 5HT2A. Su uso para el tratamiento del trastorno de ansiedad generalizada y la depresión en individuos con cáncer en etapa terminal muestra resultados prometedores en ensayos clínicos. Objetivo: Revisar la literatura sobre la eficacia y seguridad de la psicoterapia asistida con psilocibina para el tratamiento de la depresión y la ansiedad en pacientes con cáncer en riesgo de muerte. Método: Revisión bibliográfica mediante búsqueda en las bases de datos Pubmed y Medline, utilizando el término "psilocibina cancer". Se seleccionaron artículos que incluían pacientes oncológicos con riesgo de muerte por la enfermedad publicados entre 2011 y 2020. Solo se seleccionaron ensayos clínicos aleatorizados, doble ciego y controlados con placebo. Resultados: Solo 3 de los 143 artículos seleccionados cumplieron con los criterios de inclusión. Además de ser segura, los estudios han encontrado eficacia en el uso de la psilocibina para el tratamiento de los síntomas de ansiedad y depresión en pacientes. También hubo una mejora en el bienestar, el optimismo y una disminución en la angustia psicológica y existencial relacionada con el cáncer. Consideraciones: La psicoterapia asistida con psilocibina puede ser prometedora en el contexto de los cuidados paliativos de los pacientes con cáncer.
Descargas
Citas
- BREEKSEMA, Joost J. et al. Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs, v. 34, n. 9, p. 925-946, 17 ago. 2020. Disponível em: https://doi.org/10.1007/s40263-020-00748-y.
- BOKU, Shuken et al. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences, v. 72, n. 1, p. 3-12, 19 out. 2017. Disponível em: https://doi.org/10.1111/pcn.12604.
- CARBONARO, Theresa M. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, v. 30, n. 12, p. 1268-1278, 27 set. 2016. Disponível em: https://doi.org/10.1177/0269881116662634.
- CARHART-HARRIS, Robin L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, v. 113, n. 17, p. 4853-4858, 11 abr. 2016. Disponível em: https://doi.org/10.1073/pnas.1518377113.
- DAVIS, Alan K. et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 4 nov. 2020. Disponível em: https://doi.org/10.1001/jamapsychiatry.2020.3285.
- DOOLEY, Larissa N. et al. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. Neuroscience & Biobehavioral Reviews, v. 94, p. 219-237, nov. 2018. Disponível em: https://doi.org/10.1016/j.neubiorev.2018.09.006.
- DOS SANTOS, Rafael Guimarães; BOUSO, José Carlos; HALLAK, Jaime E. C. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC Psychiatry, v. 19, n. 1, 28 out. 2019. Disponível em: https://doi.org/10.1186/s12888-019-2288-z.
- ESCOBAR, J. A. C., & Roazzi, A. (2015). Substâncias Psicodélicas e Psilocibina Psychedelic Substances and Psilocybin. 1–27. Retrieved from http://neip.info/novo/wp-content/uploads/2015/04/escobarroazzi_substncias.pdf
- GEIGER, Haden A.; WURST, Madeline G.; DANIELS, R. Nathan. DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience, v. 9, n. 10, p. 2438-2447, 29 jun. 2018. Disponível em: https://doi.org/10.1021/acschemneuro.8b00186.
- GUTIERREZ, Pilar L.. O que é o paciente terminal?. Rev. Assoc. Med. Bras., São Paulo , v. 47, n. 2, p. 92, June 2001 . Available from <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302001000200010&lng=en&nrm=iso>. access on 14 Apr. 2020. https://doi.org/10.1590/S0104-42302001000200010.
- GRIFFITHS, Roland R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, v. 30, n. 12, p. 1181-1197, 30 nov. 2016. Disponível em: https://doi.org/10.1177/0269881116675513.
- GROB, Charles S. et al. Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, v. 68, n. 1, p. 71, 3 jan. 2011. Disponível em: https://doi.org/10.1001/archgenpsychiatry.2010.116.
- JOHNSON, Matthew W.; GRIFFITHS, Roland R. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, v. 14, n. 3, p. 734-740, 5 jun. 2017. Disponível em: https://doi.org/10.1007/s13311-017-0542-y.
- LEONARD, James B.; ANDERSON, Bruce; KLEIN-SCHWARTZ, Wendy. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology, v. 32, n. 12, p. 1286-1294, 5 set. 2018. Disponível em: https://doi.org/10.1177/0269881118793086.
- MACLEAN, Katherine A. et al. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, v. 51, n. 4, p. 721-737, dez. 2012. Disponível em: https://doi.org/10.1111/j.1468-5906.2012.01685.x.
- MACREADY, N. Opening Doors of Perception: Psychedelic Drugs and End-of-Life Care. JNCI Journal of the National Cancer Institute, v. 104, n. 21, p. 1619-1620, 25 out. 2012. Disponível em: https://doi.org/10.1093/jnci/djs468.
- MUTTONI, S. Classical psychedelics for the treatment of depression and anxiety: A systematic review, Journal of Affective Disorders, Volume 258, 2019, Pages 11-24, ISSN 0165-0327, https://doi.org/10.1016/j.jad.2019.07.076.
- NICHOLS, DE; JOHNSON, MW; NICHOLS, CD. Psychedelics as Medicines: (Ross et al., 2016)An Emerging New Paradigm. Clinical Pharmacology & Therapeutics, v. 101, n. 2, p. 209-219, 26 dez. 2016. Disponível em: https://doi.org/10.1002/cpt.557.
- NICHOLS, David E. The Heffter Research Institute: Past and Hopeful Future. Journal of Psychoactive Drugs, v. 46, n. 1, p. 20-26, jan. 2014. Disponível em: https://doi.org/10.1080/02791072.2014.873688.
- PAHNKE WN. Drugs and Mysticism – An analysis of the relationship between Psychedelic Drugs and the Mystical Consciousness. Thesis Presented to The Committee on Higher Degrees in History and Philosophy of Religion – Harvard University. 1963. p. 1-342.
- PRUGGER, Johanna et al. The Altered States Database: Psychometric data from a systematic literature review. Scientific Data, v. 9, n. 1, 23 nov. 2022. Disponível em: https://doi.org/10.1038/s41597-022-01822-4.
- REIFF, Collin M. et al. Psychedelics and Psychedelic-Assisted Psychotherapy. FOCUS, v. 19, n. 1, p. 95-115, jan. 2021. Disponível em: https://doi.org/10.1176/appi.focus.19104.
- ROSEMAN, Leor; NUTT, David J.; CARHART-HARRIS, Robin L. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, v. 8, 17 jan. 2018. Disponível em: https://doi.org/10.3389/fphar.2017.00974.
- ROSS, Stephen et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, v. 30, n. 12, p. 1165-1180, 30 nov. 2016. Disponível em: https://doi.org/10.1177/0269881116675512.
- SCHENBERG, Eduardo Ekman. Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology, v. 9, 5 jul. 2018. Disponível em: https://doi.org/10.3389/fphar.2018.00733.
- STUDERUS, Erich et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology, v. 25, n. 11, p. 1434-1452, 20 set. 2010. Disponível em: https://doi.org/10.1177/0269881110382466.
- THOMAS, Jane DeLima; REITSCHULER-CROSS, Eva; BLOCK, Susan D. Management of Psychosocial Issues in Terminal Illness. DeckerMed Family Medicine, 1 jul. 2013. Disponível em: https://doi.org/10.2310/fm.1224.
- VARGAS, Ana Sofia et al. Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials. Biomedicines, v. 8, n. 9, p. 331, 5 set. 2020. Disponível em: https://doi.org/10.3390/biomedicines8090331.
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
